

Anti-CD22 Therapies - Pipeline Insight, 2022

<https://marketpublishers.com/r/A46437E075C5EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: A46437E075C5EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Anti-CD22 Therapies - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anti-CD22 Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Anti-CD22 Therapies Understanding

Anti-CD22 Therapies: Overview

CD22 (Siglec 2) is a single-spanning membrane glycoprotein of 140 kDa on the surface of B cells. Plasma cells do not express the molecule. CD22 has seven extracytoplasmic Ig-like domains and belongs to the Ig superfamily. It serves as a receptor for carbohydrate determinants on a wide variety of cell surface and soluble molecules in vivo. In contrast to CD19, CD22 can act as an antagonist to B cell activation most likely by enhancing the threshold of BCR induced signals. CD22 is expressed on the surface of most B-cell leukemias and lymphomas and therefore has been explored as a target for Ab-based therapies. Research studies shows that use of chimeric antigen receptor (CAR) T-cell therapy, specific for CD22 was reported to provide high response rates for patients with B-cell acute lymphoblastic leukemia (B-ALL) who had failed chemotherapy

and/or a CD19-targeted CAR T-cell treatment. The ability of CD22 to regulate both BCR and TLRs represents an attractive therapeutic strategy for manipulating B cell responses in autoimmunity.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD22 Therapies R&D. The therapies under development are focused on novel approaches for Anti-CD22 Therapies.

Anti-CD22 Therapies Emerging Drugs Chapters

This segment of the Anti-CD22 Therapies report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anti-CD22 Therapies Emerging Drugs

SM03: SinoMab Bioscience

SM 03 is a recombinant human anti-CD22 monoclonal antibody. SM03 is a chimeric mAb specific to the B cell restricted antigen CD22 developed for the treatment of rheumatoid arthritis, and other immunological diseases such as systemic lupus erythematosus and Sjogren's syndrome. The drug is currently in Phase III clinical trial for rheumatoid arthritis in China.

AUTO3: Autolus

AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. AUTO3 is currently being tested in diffuse large B cell lymphoma in the ALEXANDER clinical trial.

Further product details are provided in the report.....

Anti-CD22 Therapies: Therapeutic Assessment

This segment of the report provides insights about the different Anti-CD22 Therapies drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Anti-CD22 Therapies

There are approx. 10+ key companies which are developing the Anti-CD22 Therapies. The companies which have their Anti-CD22 Therapies drug candidates in the most advanced stage, i.e. Phase III include, SinoMab Bioscience.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Anti-CD22 Therapies pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anti-CD22 Therapies: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Anti-CD22 Therapies therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anti-CD22 Therapies drugs.

Anti-CD22 Therapies Report Insights

- Anti-CD22 Therapies Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Anti-CD22 Therapies Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Anti-CD22 Therapies drugs?

How many Anti-CD22 Therapies drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Anti-CD22 Therapies?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anti-CD22 Therapies therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Anti-CD22 Therapies and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

SinoMab Bioscience

Autolus

Shanghai Unicar-Therapy Bio-medicine Technology

Cellectis

Allife Medical Science and Technology

Key Products

SM03

AUTO3

Anti CD22 chimeric antigen receptor T cell therapy

UCART 22

Anti-CD22 CAR NK Cells

Contents

Introduction

Executive Summary

Anti-CD22 Therapies: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Anti-CD22 Therapies – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Anti-CD22 Therapies companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Anti-CD22 Therapies Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

SM03: SinoMab Bioscience

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Anti CD22 chimeric antigen receptor T cell therapy: Shanghai Unicar-Therapy Bio-medicine Technology

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

Comparative Analysis
AUTO3: Autolus
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
Anti-CD22 Therapies Key Companies
Anti-CD22 Therapies Key Products
Anti-CD22 Therapies- Unmet Needs
Anti-CD22 Therapies- Market Drivers and Barriers
Anti-CD22 Therapies- Future Perspectives and Conclusion
Anti-CD22 Therapies Analyst Views
Anti-CD22 Therapies Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Anti-CD22 Therapies

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Anti-CD22 Therapies

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Anti-CD22 Therapies - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/A46437E075C5EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A46437E075C5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970